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Role of calcium channel blockers in the future, in view of the Patients with Hypertension (STOP; felodipine and israd-
INSIGHT Study. The data from The International Nifedipine ipine), and The International Nifedipine Intervention as
Intervention as a Goal in Hypertension Treatment (INSIGHT) a Goal in Hypertension Treatment (INSIGHT; nifedipineStudy indicate that effectively reducing blood pressure can de-
GITS). These recent studies all dealt with the elderly, increase the incidence of cardiovascular events in high risk pa-
line with the increase in that population, which, accordingtients with concomitant pathology, including diabetes and hy-
percholesterolemia, as well as in smokers and those with poor to the US Department of Health, is expected to double
family history. Old and new antihypertensive drugs were similar over the next 30 years.
in preventing cardiovascular mortality as major events. The glo- The International Nifedipine Intervention as a Goalmerular filtration rate of patients on co-amilozide went down
in Hypertension Treatment (INSIGHT) Study enrolledcompared to those on nifedipine. Metabolic parameters, as ex-
pected, were not disturbed during treatment with calcium chan- subjects from 55 to 88 years of age, and had the decided
nel blockers, in contrast to the high-dose diuretic-treated popu- advantage of addressing a hypertensive population with
lation. Ankle edema induced by nifedipine was very disturbing. other risk factors, including hypercholesterolemia, diabe-
It can be concluded that overall calcium channel blockers are
tes, smoking, left heart hypertrophy and coronary arteryneither better nor worse than conventional therapy, allowing
disease, renal involvement, and family history [2, 3]. Thisfor possible small differences in stroke (advantage to calcium
channel blockers) and myocardial infarction (advantage to di- study is especially important since the pharmacokinetics
uretics). Thus, calcium channel blockers should be included in of drugs, even within the same class, can differ enough
the future among the first choice drugs. to give each drug a different safety and efficacy profile.
The data from INSIGHT indicate that effectively re-
ducing blood pressure can decrease the incidence of car-
The Joint National Committee (JNC) V preference diovascular events in high-risk patients. Blood pressure
for beta-blockers and diuretics over calcium channel was well controlled under the study protocol, with systolic
blockers and converting enzyme inhibitors for the treat- blood pressure decreasing 173  14 to 138  12 mm Hg.
ment of hypertension is well known. Nevertheless, the Two earlier studies comparing the efficacy of calcium
seven experts on the panel who were deeply involved in channel blockers and conventional therapy did not achieve
the daily care of patients preferred drugs other than such a target value [4, 5].
beta-blockers and diuretics as first-line therapy of hyper-
Both nifedipine gastrointestinal transport system (GITS)
tension [1]. The JNC VI was more flexible, declaring
and amlodipine lowered norepinephrine levels, implyingdiuretics preferable but adding long-acting dihydropyri-
that these longer acting dihydropyridine formulationsdines as first line therapies for the elderly.
inhibit the release of norepinephrine by the adrenal me-Several studies have compared old and new antihyper-
dulla [6]. The fact that nifedipine GITS did not increasetensive drugs. The newer studies that evaluated calcium
pulse rate levels in the INSIGHT Study proves it doeschannel blockers include: Shangai Trial of Nifedipine in
not activate the sympathetic system. Heart rate in thethe Elderly (STONE; nifedipine), Systolic Hypertension
INSIGHT study fell slightly in both the diuretic- andin Europe Trial (Syst-Eur) and Systolic Hypertension in
nifedipine-treated groups.China Trial (Syst-China; nitrendipine), Hypertension Op-
INSIGHT also documented the benefits of calciumtimal Treatment (HOT; felodipine), Swedish Trial in Old
antagonists on renal function. The diverse properties of
calcium antagonists, independent of their renal microcir-
culatory effects, also afforded renal protection. This wasKey words: hypertension treatment, diuretics, dihydropyridine formu-
lations, norepinephrine, sympathetic system, nifedipine. evidenced in INSIGHT where proteinuria, one of the
possible entry criteria, accounted for more withdrawal 2002 by the International Society of Nephrology
S-32
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Determinants in Cardiovascular Disease (MONICA)
studies [2]. According to INSIGHT, the percentage of
patients with myocardial infarction was slightly higher in
the calcium channel blocker patients, but their incidence
of stroke was lower. Sudden death in patients on diuretics
was higher in the INSIGHT study. However, had sudden
death been defined as myocardial infarction—as it should
have been in 18 patients with death due to unknown
cause because of a lack of information (Fig. 2)—the ratio
of myocardial infarctions in the calcium channel blockerFig. 1. Estimated glomerular filtration rate with nifedipine GITS (),
and diuretic groups would have changed. The percentageand hydrochlorothiazide and amiloride () (P  0.05 for trend).
of myocardial infarctions would have been somewhat
higher with diuretics. This is important in view of the
claims that calcium antagonists led to coronary events
from treatment in patients on diuretics than in those on [12]. Opie pointed out design flaws in some of the studies
calcium antagonists. According to De Quattro and Lee, that Pahor included in his meta-analysis: selection bias
both nifedipine GITS and enalapril were equivalent in and precise definitions of end points like stroke, myocar-
reducing proteinuria; the glomerular filtration rate (GFR) dial infarction and heart failure [13].
of patients who received coamilozide went down in con- Lowering blood pressure also reduced left ventricular
trast to those patients who were on nifedipine treatment mass (abstract; Siva et al, J Hum Hypertens 14:854, 2000),
(Fig. 1) [7]. although it took two years before the maximal fall was
Angiotensin converting enzyme inhibitors and calcium observed. Siva et al concluded that reducing blood pres-
antagonists appear to have a beneficial or neutral effect sure determined left ventricular mass, not the type of
on the kidneys of diabetic patients, proving Parving, Tar- treatment.
now and Rossing’s view that treating high blood pressure Nifedipine proved superior to diuretics with regard
in diabetics is crucial to delaying renal nephropathy [8].
to calcified coronary atherosclerosis when examined by
The importance of decreasing diastolic blood pressure
electron beam computed tomography [14]. Comparedin the diabetic patient was proved beyond any doubt in
to the co-amilozide group, coronary calcium progressionthe HOT study, where felodipine reduced major cardio-
was significantly retarded in the nifedipine group duringvascular events together with a decrease in diastolic blood
the first year; and by the end of three years, the totalpressure. Cardiovascular events, strokes and coronary
calcium score increased 40% on nifedipine versus 78%events were fewer in the diabetic patients in the SYST-
on co-amilozide. The patients who entered the studyEUR study with nitrendipine than in the Systolic Hyper-
with calcium exhibited significant slowing of calcium pro-tension in the Elderly Program (SHEP) study with a di-
gression on nifedipine [14].uretic. Tuomilehto et al found nitrendipine particularly
There is also a preference for calcium channel blockersbeneficial in older patients with diabetes and isolated
when regarding intima-media thickness of large arteries,systolic hypertension [9].
an index of atherosclerosis. Simon et al found that the di-INSIGHT patients with diabetes also benefited from
ameter decreased more on co-amilozide than on nifedipine.nifedipine GITS, although they required more of the
Blood pressure decreased similarly in both groups [15].drug [10], and twice the number of diabetics than non-
Gluteal biopsies disclosed that long-term use of cal-diabetics required a third drug. The endpoint systolic
cium antagonists improved the structure and endothe-blood pressure was 141 in diabetics as opposed to 138
lium-dependent relaxation in small arteries. The media-in non-diabetics.
lumen ratio of resistant arteries from patients on calciumOld and new antihypertensive drugs were similar in
channel blockers became slightly but significantly largerpreventing cardiovascular mortality or major events. Ac-
than seen in normotensive controls [16].cording to Jollis et al, calcium channel blockers were no
The calcium antagonists lacidipine and nifedipine GITSworse than other antihypertensive drugs with regard to
positively affected cognitive activity, increasing alert-the incidence of myocardial infarction [11]. The Framing-
ness, memory and intellectual function, important in theham Study reported no more mortality in hypertensive
elderly. Indeed, the SYST-EUR study already reportedpatients using calcium antagonists than in those who did
reduced dementia by calcium antagonists [abstract; Al-not use this class of drugs. This was true for those with
cocer et al, J Hypertens 18(Suppl 2):S160, 1997] [17].and without coronary heart disease at baseline.
Alterations in calcium homeostasis might be critical inThe INSIGHT Study exceeded all expectations, reduc-
brain aging, making them important in Alzheimer’s dis-ing coronary endpoints much more than predicted by
either the Framingham or the Monitoring of Trends and ease [18]. Pessina et al found that nifedipine GITS and
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Fig. 2. Sudden Death and Death of “Un-
known Cause.” Cases classified by the IN-
SIGHT Study Critical Events Committee as
*lacking documentation of cardiac symptoms
within 24 hours of death or failing to meet
pre-specified definition of sudden death.
amlodipine improved several quality of life parameters, noted, well designed, carefully executed controlled studies
with long-acting calcium channel antagonists—dihydro-including vitality, and physical and social functioning [19].
Calcium antagonists, like converting enzyme inhibi- piridines—have proven the safety and efficacy of these
drugs [22]. Thus, calcium antagonists are not only drugstors, have a positive effect on serum lipids, which are
generally high in diabetic patients. Indeed, with the ex- of the present, but should be among first choice antihy-
pertensive drugs in the future, mainly in the elderly. Thisception of calcium antagonists, nearly all antihyperten-
sive agents affect serum lipids. Diuretics, on the other has been confirmed by the INSIGHT Study.
hand, cause a decrease in potassium, which was promi-
Reprint requests to Talma Rosenthal, M.D., Chorley Hypertension
nently found in the INSIGHT Study, and can lead to Research Institute, Chaim Sheba Medical Center, Tel Hashomer 52621
Israel.severe arrhythmia. They raise glucose level as well. This
E-mail: trosenth@sheba.health.gov.ilalso was seen in INSIGHT, but it must be pointed out
that the study allowed a high dosage of diuretics.
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